Antisense Technology

Compound Biological Activity Reported in Several Types of Cancer

Published in Cancer Weekly, October 7th, 1996

Genta Inc., San Diego, California, reported preclinical and interim clinical trial results showing biological activity of an antisense compound against several cancer types.

The results of the G3139 antisense compound were presented at the 12th International Roundtable on Nucleosides, Nucleotides and Their Biological Applications, held in San Diego, California, in September 1996.

The presentations, given by Dr. Lyle J. Arnold Jr., Genta, and other Genta scientists, featured results of recent preclinical (animal) studies which included anti-tumor activity of G3139 as monotherapy against breast, colon and ovarian cancers and corroboration of a previous...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1996-10-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry